Prothena (PRTA) Competitors $9.92 -0.07 (-0.70%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.82 -0.10 (-1.01%) As of 10/3/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. AUPH, SRPT, APGE, TWST, NTLA, IMCR, HROW, VERA, PAHC, and VCELShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Aurinia Pharmaceuticals (AUPH), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Intellia Therapeutics (NTLA), Immunocore (IMCR), Harrow (HROW), Vera Therapeutics (VERA), Phibro Animal Health (PAHC), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Aurinia Pharmaceuticals Sarepta Therapeutics Apogee Therapeutics Twist Bioscience Intellia Therapeutics Immunocore Harrow Vera Therapeutics Phibro Animal Health Vericel Aurinia Pharmaceuticals (NASDAQ:AUPH) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Does the media favor AUPH or PRTA? In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 2 mentions for Prothena. Prothena's average media sentiment score of 0.34 beat Aurinia Pharmaceuticals' score of 0.17 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, AUPH or PRTA? Aurinia Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Is AUPH or PRTA more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Prothena's net margin of -2,929.30%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals23.31% 20.06% 13.81% Prothena -2,929.30%-62.17%-54.43% Which has higher earnings and valuation, AUPH or PRTA? Aurinia Pharmaceuticals has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$235.13M6.35$5.75M$0.4326.40Prothena$135.16M3.95-$122.31M-$5.64-1.76 Do insiders and institutionals have more ownership in AUPH or PRTA? 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 9.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend AUPH or PRTA? Aurinia Pharmaceuticals presently has a consensus price target of $13.00, indicating a potential upside of 14.54%. Prothena has a consensus price target of $19.75, indicating a potential upside of 99.09%. Given Prothena's higher possible upside, analysts clearly believe Prothena is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Prothena 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryAurinia Pharmaceuticals beats Prothena on 12 of the 16 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$537.76M$3.33B$6.09B$10.57BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-1.7622.1477.9126.71Price / Sales3.95406.35576.77177.88Price / CashN/A47.2037.7961.25Price / Book1.109.9312.546.56Net Income-$122.31M-$52.80M$3.31B$277.70M7 Day Performance5.42%5.22%4.25%2.41%1 Month Performance20.83%13.01%7.81%9.30%1 Year Performance-41.16%25.18%71.37%31.22% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.0548 of 5 stars$9.92-0.7%$19.75+99.1%-41.0%$537.76M$135.16M-1.76130AUPHAurinia Pharmaceuticals3.1277 of 5 stars$13.07+0.5%$13.00-0.5%+61.7%$1.71B$235.13M30.40300High Trading VolumeSRPTSarepta Therapeutics4.5958 of 5 stars$18.65+7.0%$39.32+110.8%-80.9%$1.70B$1.90B-21.441,372News CoverageAPGEApogee Therapeutics2.9527 of 5 stars$37.96+3.9%$97.29+156.3%-29.9%$1.68BN/A-9.1991Positive NewsInsider TradeTWSTTwist Bioscience3.6988 of 5 stars$27.81-0.3%$49.40+77.6%-27.4%$1.68B$312.97M-19.18990Analyst ForecastNTLAIntellia Therapeutics4.3911 of 5 stars$17.26+10.7%$27.39+58.7%+13.1%$1.67B$57.88M-3.68600IMCRImmunocore2.5685 of 5 stars$33.18+1.8%$56.89+71.5%+12.2%$1.64B$310.20M-82.94320Positive NewsHROWHarrow2.9862 of 5 stars$46.09+3.9%$64.67+40.3%-8.7%$1.64B$199.61M-184.36180Trending NewsAnalyst ForecastAnalyst RevisionVERAVera Therapeutics2.7299 of 5 stars$26.11+2.0%$63.00+141.3%-25.6%$1.63BN/A-7.2940Positive NewsPAHCPhibro Animal Health4.5773 of 5 stars$38.40-3.7%$28.40-26.0%+81.4%$1.62B$1.30B32.542,475VCELVericel3.3483 of 5 stars$31.81+0.4%$60.40+89.9%-21.5%$1.60B$237.22M265.11300 Related Companies and Tools Related Companies Aurinia Pharmaceuticals Competitors Sarepta Therapeutics Competitors Apogee Therapeutics Competitors Twist Bioscience Competitors Intellia Therapeutics Competitors Immunocore Competitors Harrow Competitors Vera Therapeutics Competitors Phibro Animal Health Competitors Vericel Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredThese financial titans stride the earth, invisibleUBS says millionaire ranks have surged 5-fold — but many of these new millionaires aren’t tech moguls or Wall ...Porter & Company | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
